Alaproclate hydrochlorideProduct ingredient for Alaproclate

Name
Alaproclate hydrochloride
Drug Entry
Alaproclate

Alaproclate was developed as one of the first selective serotonin reuptake inhibitor (SSRI) antidepressants by Astra AB (now AstraZeneca) in the 1970s. Development was discontinued due to concerns over hepatotoxicity observed in animal studies. Alaproclate has also been found to act as a non-competitive NMDA receptor antagonist although without discriminative stimulus properties similar to phencyclidine.

Accession Number
DBSALT002575
Structure
Synonyms
Not Available
UNII
NIH506S9US
CAS Number
60719-83-7
Weight
Average: 292.2
Monoisotopic: 291.0792843
Chemical Formula
C13H19Cl2NO2
InChI Key
OPAKSOWFKIUFNP-UHFFFAOYSA-N
InChI
InChI=1S/C13H18ClNO2.ClH/c1-9(15)12(16)17-13(2,3)8-10-4-6-11(14)7-5-10;/h4-7,9H,8,15H2,1-3H3;1H
IUPAC Name
1-(4-chlorophenyl)-2-methylpropan-2-yl 2-aminopropanoate hydrochloride
SMILES
Cl.CC(N)C(=O)OC(C)(C)CC1=CC=C(Cl)C=C1
ChemSpider
10131704
ChEMBL
CHEMBL1256359
Predicted Properties
PropertyValueSource
Water Solubility0.0377 mg/mLALOGPS
logP2.82ALOGPS
logP2.88Chemaxon
logS-3.8ALOGPS
pKa (Strongest Basic)7.34Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count2Chemaxon
Hydrogen Donor Count1Chemaxon
Polar Surface Area52.32 Å2Chemaxon
Rotatable Bond Count5Chemaxon
Refractivity68.5 m3·mol-1Chemaxon
Polarizability27.04 Å3Chemaxon
Number of Rings1Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon